Chembio to Present at the ROTH Capital Partners 25th Annual Growth Stock
MEDFORD, N.Y., March 14, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious
diseases, announces that Lawrence Siebert, Chief Executive Officer, will
present at the ROTH Capital Partners 25th Annual Growth Stock Conference to be
held March 18-20, 2013 at The Ritz Carlton in Dana Point, California. Mr.
Siebert will be presenting Tuesday, March 19, at 3:00 p.m. (PT) with
one-on-one meetings held throughout the day to discuss the Company's strategy
for continued growth.
The Chembio presentation will be available for the public to access via the
Investor Relations section of the Chembio corporate Website, www.chembio.com
or at http://wsw.com/webcast/roth27/cemi/ where it will be archived for 90
This three-day event will feature more than 1,000 institutional investors and
more than 370 company presentations, and is designed to provide investors with
a unique opportunity to gain insight into small and mid-cap growth companies
across a variety of sectors including Business Services, Consumer, Cleantech,
Industrials & Resources, Healthcare, Metals & Mining and Technology & Media.
For more information about the conference or to schedule a one-on-one meeting
with Chembio management, please contact your ROTH representative at
1-800-933-6830 or via e-mail at email@example.com.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK^® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP^®) technology, which has significant
advantages over lateral-flow technologies.This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP^®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U. S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485. For further
information please visit www.chembio.com.
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended.Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management.Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties.Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products.Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.
CONTACT: Chembio Diagnostics
(631) 924-1135, ext. 125
Anne Marie Fields
Press spacebar to pause and continue. Press esc to stop.